For tamoxifen, its combination with NR4A1 was chosen for simulation (binding energy of −6.5 kcal/mol) primarily based on the critical regulatory role of NR4A1 in Th2-type immune responses, which are highly relevant to the pathogenesis of atopic dermatitis. The gene discussed is NR4A1; the disease is atopic eczema.